Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Evaluation framework study assessing the role, applicability and adherence to good practice of planning support tools for allocation of development aid for health in low-income and middle-income countries.
Megiddo, I; Blair, S; Sabei, D; RUIZ, F; Morton, AD;
2023
BMJ Open, (2023).13 7 10.1136/bmjopen-2022-069590.
Designing economic evaluations for transferability: A critical review and practical guide.
PITT, C; HANSON, K; Goodman, C;
2023
(2023).
The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries.
Portnoy, A; CLARK, RA; Weerasuriya, CK; Mukandavire, C; Quaife, M; Bakker, R; Garcia Baena, I; Gebreselassie, N; Zignol, M; JIT, M; WHITE, RG; Menzies, NA;
2023
BMJ global health, (2023).8 7 10.1136/bmjgh-2023-012466.
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
Portnoy, A; Arcand, J-L; CLARK, RA; Weerasuriya, CK; Mukandavire, C; Bakker, R; Patouillard, E; Gebreselassie, N; Zignol, M; JIT, M; WHITE, RG; Menzies, NA;
2023
PLoS medicine, (2023).20 7 10.1371/journal.pmed.1004252.
Cost-effectiveness of measles and rubella elimination in low-income and middle-income countries.
Levin, A; Burgess, C; Shendale, S; Morgan, W; Cw Hutubessy, R; Measles–rubella Eradication Modelling Group,; JIT, M; Measles-rubella Eradication Modelling Group,;
2023
BMJ global health, (2023).8 7 10.1136/bmjgh-2022-011526.
Is Full Health Technology Assessment Cost-Effective? Adapting It Could be More Efficient.
Vassall, A; RUIZ, F;
2023
(2023).
Making Implementation Feasible: Accounting for Constraints in Priority Setting Under Limited Resources.
RUIZ, F; Umuhoza, S; Baltussen, R; Madriz Montero, A; BOZZANI, F; Kumar, M; Huda, M;
2023
(2023).
Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
Fleming, JA; Baral, R; Higgins, D; Khan, S; Kochar, S; Li, Y; Ortiz, JR; Cherian, T; Feikin, D; JIT, M; Karron, RA; Limaye, RJ; Marshall, C; Munywoki, PK; Nair, H; Newhouse, LC; Nyawanda, BO; Pecenka, C; Regan, K; Srikantiah, P; Wittenauer, R; Zar, HJ; Sparrow, E;
2023
Vaccine, (2023).41 Sup, 10.1016/j.vaccine.2022.09.081.
The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.
Hutubessy, R; Lauer, JA; Giersing, B; Sim, SY; JIT, M; Kaslow, D; Botwright, S;
2023
BMC medicine, (2023).21 1 10.1186/s12916-023-02929-0.
Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data.
Feng, S; McLellan, J; Pidduck, N; Roberts, N; Higgins, JP T; Choi, Y; Izu, A; JIT, M; Madhi, SA; Mulholland, K; Pollard, AJ; Temple, B; Voysey, M;
2023
EClinicalMedicine, (2023).61, 10.1016/j.eclinm.2023.102073.